Pfizer Submits Phase 1 Aftereffects of Covid-19 Immunization Promoter Preliminary to Fda for Survey
Pfizer on Monday announced it submitted data to the Food and Drug Administration regarding the results of Phase 1 trials for a potential COVID-19 vaccine booster shot for people having low immune power…
In a press release, Pfizer added some words and said it would also submit the data to the European Medicines Agency in the coming weeks.
Late last month, Pfizer said that earlier studies showed that the third dose of its COVID-19 vaccine, taken about eight or nine months after the first two doses, produced high levels of antibodies that fight off the virus.
Read More: News Study Finds Genetic Clue to COVID-19 Risk! Read Full News Here
In its findings, Pfizer said data revealed that after the third dose of its vaccine, the level of antibodies effective in opposition to the delta variant could be more than five times higher than after a second dose of the vaccine in peoples of age around 18 to 55, and more than 11 times higher in people as compared to the age 65 to 85.
On this, we see Dr Ugur Sahin, the CEO and Co-founder of BioNTech(the man behind the making of the vaccine) said-
“We continuously strive to stay at least one step ahead of the virus. This is why we aim to expand access to our vaccine for people around the world and are working on various approaches as part of our comprehensive strategy to address the virus and its variants today as well as in the future,”
“This initial data indicates that we may preserve and even exceed the high levels of protection against the wild-type virus and relevant variants using the third dose of our vaccine. A booster vaccine could help reduce infection and disease rates in people who have previously been vaccinated and better control the spread of virus variants during the coming season.”
Read More: Lab Study Claims A Common Drug Can Decrease COVID-19 Infection By Up To 70% Read In Detail
Testing for a booster shot of the vaccine is under testing( phase 2 trials), and Pfizer added on Monday that Phase 3 trials would begin “shortly.”
Pfizer on Monday reported it submitted information to the Food and Drug Administration with respect to the consequences of Phase 1 preliminaries for a potential COVID-19 immunization promoter shot.
In an official statement, Pfizer said it would likewise present the information to the European Medicines Agency in the coming weeks.
At the end of last month, Pfizer said that underlying investigations showed that the third portion of its COVID-19 immunization, required around eight or nine months after the initial two dosages, delivered undeniable degrees of antibodies that ward off the infection.
In its discoveries, Pfizer said information proposes that get-togethers third portion of its immunization, the degree of antibodies viable against the delta variation could be in excess of multiple times higher than following a second portion of the antibody in individuals ages 18 to 55, and in excess of multiple times higher in individuals ages 65 to 85.
Testing for a promoter shot of the antibody is right now in Phase 2 preliminaries, and Pfizer said Monday that Phase 3 preliminaries would start “quickly.”
Stay tuned with The East County Gazette to get more latest and news update.
